Overview
Switzerland eye care firm's Q1 sales up 10%, slight miss vs analyst expectations
Adjusted EPS for Q1 rose 16%, beating analyst expectations
Company announced new $1.5 bln share repurchase program over three years
Outlook
Alcon maintains 2026 net sales growth guidance at +5% to +7% constant currency
Company raises 2026 core diluted EPS growth outlook to +10% to +13% constant currency
Alcon expects a full-year tariff impact of $100 mln to $150 mln in 2026
Result Drivers
NEW PRODUCT LAUNCHES - Co said Q1 growth was driven by new product launches including Unity VCS and CS, PanOptix Pro, Tryptyr and Precision7
EQUIPMENT/OTHER GROWTH - Equipment/other net sales rose 27%, led by recent equipment launches including the Unity platform
DRY EYE PRODUCTS - Ocular health net sales grew 13%, led by dry eye products including Tryptyr and Systane
Company press release: ID:nBw4BRCkRa
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
Slight Miss*
$2.69 bln
$2.71 bln (13 Analysts)
Q1 Adjusted EPS
Beat
$0.85
$0.81 (13 Analysts)
Q1 EPS
$0.39
Q1 Core Operating Margin
21.20%
Q1 Operating Margin
10.90%
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Alcon AG is CHF82.00, about 40.8% above its May 5 closing price of CHF58.22
The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 24 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)